MicMac - you are correct. The aviptadil trial started with 2 primary outcomes: mortality at 5 days and PO2 at 5 days. They changed that on Nov. 25 (study version 16) to resolution of respiratory failure with concurrent survival through day 28.
You can see the first and last versions side-by-side at this link.